MindMed to Present at Leerink’s Global Healthcare Conference 2025
Get Alerts MNMD Hot Sheet
Join SI Premium – FREE
NEW YORK--(BUSINESS WIRE)-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will present at Leerink’s Global Healthcare Conference:
-
Leerink’s Global Healthcare Conference
- Format: Fireside Chat and 1x1 Meetings
- Date: March 11, 2025 at 3:40 PM ET
- Location: Miami Beach, FL
- Webcast Link: Leerink’s Global Healthcare Conference 2025
Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following each event.
About MindMed
MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on Nasdaq under the symbol MNMD.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250304577180/en/
For Media: [email protected]
For Investors: [email protected]
Source: Mind Medicine Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- “International Consumer's Symposium in Tokushima 2026” to be livestreamed on October 17
- Suphini Empowers Prestigious Italian Dance Shoe Brand’s Product Line Upgrade and European Market Expansion
- QILEE Launches Advanced Buried Modular AO+MBR Integrated Wastewater Treatment System for Global Water Challenges
Create E-mail Alert Related Categories
Business Wire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share